HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Autoantibodies to human alpha6 integrin in patients with bullous pemphigoid.

Abstract
Bullous pemphigoid (BP) is characterized immunologically by tissue-bound and circulating autoantibodies targeting the hemidesmosomal proteins BP230 and BP180. Recent evidence suggests a pathophysiological role for autoantibodies against alpha6 integrin in the subepidermal blister formation of oral pemphigoid. The objective of our study was to investigate the presence of anti-alpha6 integrin antibodies in patients with classical BP. The autoantibody profiles of 30 patients with BP, 10 patients with pemphigus vulgaris, and 20 healthy persons were identified. With the use of PeptideStructure and PlotStructure software, four different antigenic epitopes for alpha6 integrin were predicted, and their fusion recombinant constructs were prepared in an E. coli expression system. Sera were tested for alpha6 integrin autoantibodies by an ELISA technique. Altogether, 52% of the patients with BP displayed circulating antibodies against at least one recombinant protein. Our findings provide the first evidence for the presence of anti-alpha6 integrin antibodies in patients with classical BP.
AuthorsMária Kiss, Adám Perényi, Ilona Marczinovits, János Molnár, Attila Dobozy, Lajos Kemény, Sándor Husz
JournalAnnals of the New York Academy of Sciences (Ann N Y Acad Sci) Vol. 1051 Pg. 104-10 (Jun 2005) ISSN: 0077-8923 [Print] United States
PMID16126949 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Autoantibodies
  • Integrin alpha6
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Autoantibodies (blood)
  • Female
  • Humans
  • Integrin alpha6 (immunology)
  • Male
  • Middle Aged
  • Pemphigoid, Bullous (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: